

Datasheet for ABIN703077

**anti-TCP1 alpha/CCTA antibody (pSer455) (Biotin)**[Go to Product page](#)

## Overview

|                      |                                                                                                                        |
|----------------------|------------------------------------------------------------------------------------------------------------------------|
| Quantity:            | 100 µL                                                                                                                 |
| Target:              | TCP1 alpha/CCTA (TCP1)                                                                                                 |
| Binding Specificity: | pSer455                                                                                                                |
| Reactivity:          | Human                                                                                                                  |
| Host:                | Rabbit                                                                                                                 |
| Clonality:           | Polyclonal                                                                                                             |
| Conjugate:           | This TCP1 alpha/CCTA antibody is conjugated to Biotin                                                                  |
| Application:         | ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro)) |

## Product Details

|                   |                                                                                                          |
|-------------------|----------------------------------------------------------------------------------------------------------|
| Immunogen:        | KLH conjugated synthetic phosphopeptide derived from human p63 around the phosphorylation site of Ser455 |
| Isotype:          | IgG                                                                                                      |
| Cross-Reactivity: | Human                                                                                                    |
| Purification:     | Purified by Protein A.                                                                                   |

## Target Details

|                   |                                       |
|-------------------|---------------------------------------|
| Target:           | TCP1 alpha/CCTA (TCP1)                |
| Alternative Name: | P63 ( <a href="#">TCP1 Products</a> ) |

## Target Details

|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Background: | <p>Synonyms: p63 phospho S455, p63 phospho Ser455, p-p63 Ser455, AIS, Amplified in squamous cell carcinoma, Bp51A, Bp51B, p63 Alpha, Chronic ulcerative stomatitis protein, CUSP, DN p63 alpha 1, DNp63, EEC3, Keratinocyte transcription factor, Keratinocyte transcription factor KET, KET, LMS, NBP, OFC8, p40, p51, P51/P63, p53 like transcription factor, p53 related protein, p53-related protein p63, p53CP, p63, P73, p73H, p73L, RHS, SHFM4, TP53CP, TP53L, TP63, TP73, TP73L, Transformation related protein 63, Trp53rp1, Trp63, Tumor protein 63, tumor protein 63 kDa with strong homology to p53, Tumor protein p53-competing protein, Tumor protein p53-like, tumor protein p63, Tumor protein p73, tumor protein p73-like, P63_HUMAN.</p> <p>Background: This gene encodes a member of the p53 family of transcription factors. An animal model, p63 <sup>-/-</sup> mice, has been useful in defining the role this protein plays in the development and maintenance of stratified epithelial tissues. p63 <sup>-/-</sup> mice have several developmental defects which include the lack of limbs and other tissues, such as teeth and mammary glands, which develop as a result of interactions between mesenchyme and epithelium. Mutations in this gene are associated with ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3), split-hand/foot malformation 4 (SHFM4), ankyloblepharon-ectodermal defects-cleft lip/palate, ADULT syndrome (acro-dermato-ungual-lacrima-tooth), limb-mammary syndrome, Rap-Hodgkin syndrome (RHS), and orofacial cleft 8. Both alternative splicing and the use of alternative promoters results in multiple transcript variants encoding different proteins. Many transcripts encoding different proteins have been reported but the biological validity and the full-length nature of these variants have not been determined. [provided by RefSeq, Jul 2008].</p> |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|          |      |
|----------|------|
| Gene ID: | 8626 |
|----------|------|

## Application Details

|                    |                                    |
|--------------------|------------------------------------|
| Application Notes: | IHC-P 1:200-400<br>IHC-F 1:100-500 |
| Restrictions:      | For Research Use only              |

## Handling

|                |                                                                                                             |
|----------------|-------------------------------------------------------------------------------------------------------------|
| Format:        | Liquid                                                                                                      |
| Concentration: | 1 µg/µL                                                                                                     |
| Buffer:        | Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol. |
| Preservative:  | ProClin                                                                                                     |

## Handling

---

|                    |                                                                                                                    |
|--------------------|--------------------------------------------------------------------------------------------------------------------|
| Precaution of Use: | This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only. |
| Storage:           | -20 °C                                                                                                             |
| Storage Comment:   | Store at -20°C for 12 months.                                                                                      |
| Expiry Date:       | 12 months                                                                                                          |